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The term hemophagocytosis describes the
pathologic finding of activated macrophages,
engulfing erythrocytes, leukocytes, platelets, and
their precursor cells (Figure 1) (1). This
phenomenon is an important finding in patients
with hemophagocytic syndrome, more properly
referred to as hemophagocytic lymphohistiocyto-
sis (HLH) (2). HLH is a distinct clinical entity
characterized by fever, pancytopenia, splenome-
galy, and hemophagocytosis in bone marrow,
liver, or lymph nodes. The syndrome, which has
also been referred to as histiocytic medullary
reticulosis, was first described in 1939 (3). HLH
was initially thought to be a sporadic disease
caused by neoplastic proliferation of histiocytes.
Subsequently, a familial form of the disease (4)
(now referred to as familial hemophagocytic
lymphohistiocytosis [5]) was described. However,
the nearly simultaneous development of fatal
HLH by a father and son in 1965 indicated that
infection might play a role (6).
HLH has since been associated with a variety
of viral, bacterial, fungal, and parasitic infec-
tions, as well as collagen-vascular diseases (7-11)
and malignancies, particularly T-cell lymphomas
(12-14). This diversity has prompted the
suggestion that HLH secondary to an underlying
medical illness should be designated reactive
hemophagocytic syndrome. The association
between HLH and infection is important because
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Hemophagocytic lymphohistiocytosis (HLH) is an unusual syndrome characterized
by fever, splenomegaly, jaundice, and the pathologic finding of hemophagocytosis
(phagocytosis by macrophages of erythrocytes, leukocytes, platelets, and their
precursors) in bone marrow and other tissues. HLH may be diagnosed in association
with malignant, genetic, or autoimmune diseases but is also prominently linked with
Epstein-Barr (EBV) virus infection. Hyperproduction of cytokines, including interferon-γ
and tumor necrosis factor-α , by EBV-infected T lymphocytes may play a role in the
pathogenesis of HLH. EBV-associated HLH may mimic T-cell lymphoma and is treated
with cytotoxic chemotherapy, while hemophagocytic syndromes associated with
nonviral pathogens often respond to treatment of the underlying infection.
Figure 1. Hemophagocytosis in the bone marrow of an
18-year-old woman with Epstein-Barr virus (EBV)-
associated hemophagocytic lymphohistiocytosis. The
patient visited her physician in September 1997 with
pharyngitis and an elevated heterophile agglutinin
titer. She was diagnosed with infectious mononucleo-
sis, and her symptoms resolved in 2 weeks.
Approximately 2 months later, she had persistent,
spiking fevers and became jaundiced; her immunoglo-
bulin (Ig) M to EBV capsid antigen was positive; and
EBV capsid IgG and nuclear IgG were negative. She
had pancytopenia and was hospitalized. Bone marrow
evaluation revealed a hypocellular marrow, with
active hemophagocytosis. The macrophage in the
center of this image appears “stuffed” with
phagocytosed erythrocytes. Phagocytosis of platelets
and leukocytes by macrophages was also seen (not
shown). The patient was treated with intravenous
immunoglobulin, steroids, and cyclosporine A, but not
etoposide. Her condition worsened; she had respira-
tory, renal, and hepatic failure; and she died of an
intracerebral hemorrhage on hospital day 34, 3 1/2
months after her initial illness.
Original photomicrograph 100X magnification with oil im-
mersion, courtesy of Frank Evangelista, Beth Israel Deaconess
Medical Center. Photomicrograph published in Blood
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1) both sporadic and familial cases of HLH are
often precipitated by acute infections; 2) HLH
may mimic infectious illnesses, such as over-
whelming bacterial sepsis and leptospirosis (15);
3) HLH may obscure the diagnosis of a
precipitating, treatable infectious illness (as
reported for visceral leishmaniasis [16]); and 4) a
better understanding of the pathophysiology of
HLH may clarify the interactions between the
immune system and infectious agents.
This article describes the clinical features
and epidemiology of HLH and summarizes its
association with infection; reviews evidence that
this syndrome results from disordered cellular
immunity; outlines options for treatment of
patients with infection-associated HLH; and
discusses issues related to hemophagocytosis in
genetic, malignant, and autoimmune disease.
The genetic basis of hemophagocytic syndromes
has been reviewed in detail (17).
Clinical Features
Clinical criteria for the diagnosis of HLH,
proposed by the Histiocyte Society (2), include
clinical, laboratory, and histopathologic features
(Table). Fever and splenomegaly are the most
common clinical signs, but hepatomegaly,
lymphadenopathy, jaundice, and rash are also
seen. The rash is commonly described as
maculopapular, but nodular eruptions have also
been described (22). Of central nervous system
manifestations, encephalopathy, meningismus,
and seizures are the most commonly reported
(23,24). These clinical findings may suggest an
acute viral infection, such as Epstein-Barr virus
(EBV), cytomegalovirus (CMV) infection, viral
hepatitis, or acute HIV seroconversion, a
situation complicated by the association of these
infections with HLH.
The most prominent laboratory abnormali-
ties noted are cytopenias, which may be
profound. Serum chemistry findings may suggest
hemolysis, with hyperbilirubinemia and eleva-
tion of lactate dehydrogenase. Most patients
have hypertriglyceridemia and marked elevation
of ferritin (25,26). Serum fibrinogen is typically
low, and there may be disseminated intravascu-
lar coagulation (18). Elevated circulating fibrin
degradation products and serum ferritin in
patients with HLH appear to be associated with
increased risk for death (27).
Histopathologically, hemophagocytosis is
seen in bone marrow, spleen, and lymph nodes
(1,28) and occasionally the central nervous
system (23,29) and skin (22). Activated macroph-
ages may engulf erythrocytes, leukocytes, and
platelets, their precursors, and cellular frag-
ments. These cells appear “stuffed” with other
blood cells. Hemophagocytosis may be present in
the liver, but infiltration of the hepatic portal
tracts with lymphocytes is also common (1,28).
Epidemiology
HLH appears to affect all ages, although the
hereditary and sporadic cases are reported
primarily in children (30); a crude annual
incidence of 1.2 cases of familial hemophagocytic
lymphohistiocytosis per million children has
been reported in Sweden (19). Large series of
HLH cases have been reported in Hong Kong
(18,31) and Taiwan (12,32), but whether the
incidence of HLH is higher in Asia than in Europe
or North America is not known. A seasonal
pattern has been suggested in which cases may
occur more often in the summer (32).
The familial form of HLH occurs in young
children as a genetic disorder with autosomal
recessive inheritance; possible loci for a
responsible gene or genes have recently been
mapped to the long arms of chromosomes 9 (33)
and 10 (34). HLH may also occur as a
complication of Chediak-Higashi syndrome (35)
or after EBV infection in patients with X-linked
lymphoproliferative syndrome (36). In these
patients, fatal infectious mononucleosis may be
pathologically indistinguishable from HLH (37).
In 1979, HLH was described in a cohort of
patients who had serologic evidence of recent
Table. Clinical signs and laboratory abnormalities
associated with hemophagocytic lymphohistiocytosis
% of patients
Clinical sign  affected Reference
  Fever* 60-100 5,18-21
  Splenomegaly* 35-100 5,19-21
  Hepatomegaly 39-97 5,19-21
  Lymphadenopathy 17-52 5,18-21
  Rash   3-65 5,18-21
  Neurologic signs   7-47 19,21
Laboratory abnormality
  Anemia* 89-100 5,19,20
  Thrombocytopenia* 82-100 5,19,20
  Neutropenia* 58-87 5,19,21
  Hypertriglyceridemia* 59-100 5,19,21
  Hypofibrinogenemia* 19-85 5,19,21
  Hyperbilirubinemia 74 19
*Proposed diagnostic criterion for HLH (2)603
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viral infections (38), and virus-associated
hemophagocytic syndrome was proposed as a
distinct clinical entity. Subsequently, HLH has
been reported in association with a variety of
infections, and the term reactive hemophagocytic
syndrome has been suggested to distinguish
HLH associated with an identifiable infectious or
noninfectious etiology from its hereditary forms.
However, the reactive and hereditary forms of
the disease are difficult to distinguish; for
example, patients with familial forms of HLH
may have hemophagocytic syndrome after a
documented viral infection (39).
HLH and Infection
Case reports and case series on the
association of infections and HLH are summa-
rized at URL:http://www.cdc.gov/ncidod/eid/
vol6no6/fisman_refs.htm.
Disseminated infection with an unusual
organism in a patient with HLH may represent
secondary infection in an immunocompromised
host; however, the resolution of HLH following
treatment of infection suggests that, in many cases,
HLH is secondary to the underlying infection.
A diagnosis that takes into account all the
underlying diseases associated with HLH would
not be practical, and formal guidelines for
evaluating patients with suspected infection-
associated HLH have not been established.
Nevertheless, all patients meeting the criteria for
HLH should undergo initial diagnostic tests that
include routine cultures of blood and urine and
chest radiography to screen for such infections as
miliary tuberculosis. Attempts should be made to
screen for infection with EBV, CMV, and
parvovirus B19, either through serologic testing
or polymerase chain reaction, in-situ hybridiza-
tion, or (in the case of CMV) immunofluorescent
antigen testing. Serologic testing for HIV and
human herpesvirus-6 infection should also be
considered, and throat and rectal swabs should
be taken for viral culture. Because of the
association between HLH and fungal infections,
lysis-centrifugation blood cultures and fungal
antigen testing should be considered for all
patients with HLH. Even if an infection known to
be associated with HLH has been confirmed, cell
marker and T-cell receptor gene rearrangement
tests should be performed on bone marrow or
other tissue specimens to determine whether an
underlying T-cell lymphoma is present.
 Extensive testing for underlying infecting
organisms should be guided by epidemiologic
data and the patient’s medical history. For
example, in a patient with underlying HIV
infection, HLH has been associated with infections
that commonly affect patients with AIDS (e.g.,
pneumococcal disease, pneumocystosis, histo-
plasmosis, and infection with Penicillium
marneffei) and with T-cell lymphoma. Patients
with a history of travel or animal exposure should
be screened for such infections as leishmaniasis,
brucellosis, rickettsioses, and malaria. In bone
marrow transplant patients, attempts should be
made to isolate adenovirus from urine, nasopha-
ryngeal and rectal swabs, and tissue specimens.
Because so many immunologic, neoplastic,
genetic, and infectious disorders may be
associated with HLH, clinicians should work
closely with pathologists and microbiologists to
clearly define precipitating or underlying
illnesses.
Pathophysiology
Phagocytosis of blood cells and their
precursors is a hallmark of hemophagocytic
syndromes. Hemophagocytosis is achieved mostly
by monocytes and macrophages, and nitro-blue
tetrazolium reduction by monocytes from pa-
tients with HLH is approximately six times that
of control monocytes (40). Splenic macrophages
from patients with HLH exhibit an activated
phenotype with increased expression of MHC
class I and II molecules and increased M-CSF
receptor expression (41). Phagocytosis of plate-
lets in HLH may be enhanced by increases in anti-
platelet immunoglobulin (Ig) G, which has been
reported in parvovirus B19-associated HLH (42).
Excessive activation of monocytes in HLH
may be due to stimulation by high levels of
activating cytokines. High levels of interferon-γ
(IFN-γ ) (43-45), soluble interleukin-2 receptor
(43,46), tumor necrosis factor-α   (TNF-α ) (44,47,48)
interleukin-1 (49), and interleukin-6 (43) have
been demonstrated, suggesting that elaboration
of activating cytokines by T-helper cells promotes
activation of macrophages in this disease (Figure
2). Higher levels of IFN-γ   and TNF-α   correlate
with poor clinical outcome in children with virus-
associated HLH (45,49).
Recently, oversecretion of interleukin-18 by
monocytes in patients with HLH has been
described (50); interleukin-18 production may
further enhance TNF-α   and IFN-γ   production by604
Synopsis
Emerging Infectious Diseases Vol. 6, No. 6, November–December 2000
T-lymphocytes and NK cells, as well as induce Fas
ligand expression on lymphocytes, which enhances
their cytotoxic effect. Serum levels of soluble Fas
ligand, which can trigger apoptosis in such Fas-
expressing tissues as the kidney, liver, and heart,
also appear to be increased in HLH (51).
The exact mechanisms by which abnormal
cytokine elaboration by T lymphocytes results in
HLH remain unclear. However, data from
patients with EBV-associated HLH, as well as
HLH associated with EBV-positive T-cell lym-
phomas, may be instructive. Although T
lymphocytes lack the putative EBV receptor
CD21, the presence of episomal EBV genome in
T-cell lymphomas (52,53) and T lymphocytes
from patients with virus-associated HLH is well
described (54,55). EBV-positive T-cell lympho-
mas appear to elaborate TNF-α   more frequently
than either EBV-positive B-cell lymphomas or
EBV-negative T-cell lymphomas (53).
Lay and colleagues induced the expression
of CD21 in T-lymphoma cell lines and
subsequently infected these cells with EBV.
High levels of TNF-α  , IFN-γ  , and IL-1α   were
secreted by these cells after EBV infection; when
the lymphocytes were co-cultured with mono-
cytes, enhanced phagocytosis by monocytes was
observed. The enhanced phagocytosis was
eliminated by the addition of antibodies against
TNF-α   and IFN-γ   (53).
The clonal expansion of EBV-infected T
lymphocytes has been demonstrated in both
EBV-associated HLH (55-57) and EBV-positive
T-cell lymphoma (53) by the presence of
homogeneous viral terminal repetitive se-
quences. EBV-infected cells stain positive for
such T-lymphocyte markers as CD45RO and T-
cell receptor-ß (54,55). Clonality of infected T
lymphocytes is further suggested by the finding
of monoclonal rearrangements of the T-cell
receptor-ß gene in EBV-associated HLH (58).
The distinction between the monoclonal
proliferation of T lymphocytes seen in EBV-
associated HLH and EBV-positive T-cell lympho-
mas may describe extremes of a spectrum of
disordered T-lymphocyte proliferation and
cytokine elaboration following EBV infection of T
lymphocytes. Elaboration of such viral proteins
as LMP1, essential to the immortalization of
EBV-infected B-lymphocytes, may affect EBV
infection of T lymphocytes, although studies
suggest otherwise (59). It is also unclear whether
clonal proliferation of T lymphocytes occurs in
HLH associated with pathogens other than EBV.
The fact that these syndromes seem more likely
to resolve with control of the underlying infection
suggests that this may not be the case. The
apparent utility of cyclosporin A in HLH (60-62)
and the morphologic similarity of the liver
disease seen in HLH to acute graft rejection in
transplant patients (1) lend further credence to
the role of lymphocytes as central to the
pathogenesis of HLH.
The pathophysiology of infection-associated
HLH following infection with nonviral pathogens
may also be related to production of high levels of
activating cytokines by host lymphocytes and
monocytes. The relative frequency of association
between infecting organisms (e.g., Mycobacte-
rium tuberculosis, Salmonella Typhi, and Leishma-
nia sp.) that trigger a TH1 immune response and
reactive hemophagocytic syndromes might sug-
gest that the syndromes result from a poorly
Figure 2. Schematic representation of possible
immunopathologic mechanisms in infection-associ-
ated hemophagocytic lymphohistiocytosis (HLH). In
Epstein-Barr virus (EBV)-associated HLH, infection
of T lymphocytes results in clonal proliferation, with
production of high levels of activating cytokines.
Elaboration of TNF-α   and other cytokines causes fever
and systemic illness. TNF-α  and IFN-γ  production
contributes to macrophage activation with resulting
hemophagocytosis, as demonstrated by the ability of
anti-TNF-α  and anti-IFN-γ  antibodies to attenuate
hemophagocytosis. The immunopathology of infection
with nonviral pathogens is less well understood, but
may be related to exaggerated production of TNF-α
and IFN-γ  in response to infection. TNF-α  = tumor
necrosis factor-α ; IFN-γ  = interferon-gamma; IL-1 =
interleukin-1; IL-2 = interleukin-2; IL-6 = interleukin-
6; IL-18 = interleukin-18; sFasL = soluble Fas ligand;
T = T-lymphocyte; M = macrophage; EBV = Epstein-
Barr virus.605
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regulated or inappropriate TH1 response to
intracellular pathogens. However, Tsuda and
colleagues found no evidence of a marked shift
towards a TH1 cytokine profile in patients with
HLH associated with nonviral infections (63).
Prognosis and Therapy
Because these disorders are rare, no controlled
clinical trials of therapy have been performed.
For patients with reactive HLH associated with
pathogens other than EBV, supportive care and
treatment of the underlying infection is associated
with recovery in 60%-70% (20,64). Among adults
with HLH, age >30 years appears to be associated
with an increased risk for death (27).
Epstein-Barr virus-associated HLH is almost
universally fatal if untreated, with death usually
resulting from hemorrhage, infection, or
multiorgan failure (64,65). The poor prognosis of
this syndrome suggests that patients should be
treated initially with combination chemotherapy
and immunotherapy, regardless of whether they
are thought to have familial HLH. Chemotherapy
with etoposide (which is toxic to macrophages)
and dexamethasone is recommended, with the
use of intrathecal methotrexate in patients with
neurologic symptoms or persistent cerebrospinal
fluid abnormalities (66-69). In a group of children
with EBV-associated HLH, investigators induced
complete remission (median 15 months) in 15 of
17 patients (68). The increasing recognition of the
important role of T lymphocytes in HLH has led
to the recommendation that chemotherapy be
combined with cyclosporin A immunotherapy
(60-62,67). Antithymocyte globulin may also
have a role in therapy (60).
HLH associated with viral infection may be
difficult to distinguish from familial HLH
triggered by a viral infection (39), although
familial HLH should be considered more likely in
infants even in the absence of a positive family
history (19). The distinction is important, as
allogeneic bone marrow transplantation is the
therapy of choice in patients with familial HLH
who attain remission (67,70). In patients without
a clear diagnosis of familial HLH, bone marrow
transplantation should be considered if remis-
sion is not attained by 8 weeks of chemotherapy
and immunotherapy. Patients in remission
without a clear diagnosis of familial HLH should
be monitored closely for signs of relapse (67).
The role of intravenous immunoglobulin in
the treatment of HLH is unclear. Remission after
such therapy has been reported in adults and
older children with underlying immune dysfunc-
tion (71,72). However, Chen and colleagues noted
remission in only two of nine children with virus-
associated HLH treated with intravenous
immunoglobulin alone (65).
Acyclovir does not appear to be useful in the
treatment of EBV-associated HLH. However,
resolution of HLH associated with other viral
pathogens has been reported after antiviral
chemotherapy. For example, adenovirus-associ-
ated HLH in a bone marrow transplant patient
was reported to resolve with vidarabine (73),
while human herpesvirus-8-associated HLH in a
patient with HIV infection appeared to improve
with the use of foscarnet (74).
Conclusions
HLH and related hemophagocytic syndromes
are uncommon but severe illnesses associated
with a variety of infectious agents, as well as
genetic, neoplastic, and autoimmune diseases.
HLH in the context of infection is best described
as part of a spectrum of EBV-associated illness
resulting in clonal proliferation of T-lympho-
cytes, with excessive activation of macrophages.
This syndrome may be difficult to distinguish
from T-cell lymphoma and should be treated
aggressively with etoposide-based chemothera-
peutic regimens.
Hemophagocytic syndromes associated with
other infectious illnesses, including sepsis,
typhoid fever, tuberculosis, and leishmaniasis,
may resolve with treatment of the underlying
infection, and their recognition is important as
they may mimic malignant disease. Further
study of these reactive hemophagocytic syn-
dromes may yield important insights into the
biology of macrophage activation.
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